ClinicalTrials.gg
CompletedNCT03439748TADUpdated Jun 12, 2024Results posted

Treatment for Affect Dimensions

An interventional study of Positive Affect Treatment and Negative Affect Treatment in Depression and Anxiety, sponsored by University of California, Los Angeles. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-06-12.

Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-13

Among 81 studies in Depression by University of California, Los Angeles — 12 open to participants now, 12 under way, none of them phase 3. Depression · University of California, Los Angeles.

Enrollment
34th of 74
85 · median 76
Started
2019
with 1 other
No phase
45 of 81
7 open now
Registered
43rd of 81
by date

Among the 81 studies in Depression by University of California, Los Angeles, this one is the 34th largest by enrollment of the 74 interventional ones that give a count, is one of 2 that started in 2019, is one of 45 with no phase, and was the 43rd registered.

Depression

8,582 studies on the registry are indexed under Depression; 1,723 are open to participants now.

Browse Depression studies →

Open to participants now

12 of the 81 studies in Depression by University of California, Los Angeles are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 1,089 Depression studies recruiting now, 470 (43%) set no upper age limit and 519 (48%) stop at 75 or younger; 203 take children under 18; 311 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Depression by University of California, Los Angeles, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and targets of Positive Affect Treatment, a psychotherapy specifically aimed at enhancing reward sensitivity in individuals with low positive affect (a core feature of anhedonia) in the context of depression or anxiety.

Target enrollment is 68 male and female participants with low positive affect and depression or anxiety and impaired functioning, between the ages of 18 and 65 years, who will be randomized to either Positive Affect Treatment or Negative Affect Treatment (designed to reduce threat sensitivity). Participants will complete laboratory tests, psychiatric assessments, and self-report questionnaires as part of the study.

The total length of participation is around 4 months.

Read the detailed description

Low positive affect in the context of depression or anxiety has been relatively resistant to pharmacological and psychological treatments. Newer treatments that focus upon positivity or reward sensitivity have shown promising results.

As an NIMH funded R61 phase trial, the purpose of the current randomized controlled trial is to evaluate the efficacy and targets of Positive Affect Treatment (designed to augment reward sensitivity) for individuals with low positive affect in the context of depression or anxiety symptoms. Targets include behavioral, cognitive, physiological and experiential measures of three reward processes: reward anticipation, response to reward attainment, and reward learning. Specificity of target engagement is assessed by comparison with Negative Affect Treatment, designed to reduce threat sensitivity.

Clinical outcomes are assessed at baseline and either weekly or at Week 5, Week 10, and Week 15 (post). Targets are assessed at baseline, Week 5, Week 10, and Week 15. Statistical models evaluate whether change in outcomes and change in target measures are greater as a result of Positive Affect Treatment compared to Negative Affect Treatment and whether changes in target measures correlate with changes in outcome measures.

Target enrollment is 68 male and female participants with low positive affect and depression or anxiety and impaired functioning between the ages of 18 and 65 who will be randomized to Positive Affect Treatment or Negative Affect Treatment, each comprising 15 individual psychotherapy sessions.

Participants will complete laboratory tests and psychiatric assessments and self-report questionnaires as part of the study. Total length of participation is around 4 months.

03

Conditions studied

  • Depression
  • Anxiety
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • English-speaking
  • Low positive affect indexed by less than or equal to 24 on the positive affect subscale of the PANAS (i.e., PANAS-P); and scores of greater than or equal to 11 for depression, greater to or equal to 6 for anxiety, or greater to or equal to 10 for stress on the Depression, Anxiety, and Stress Scale; and scores of greater than or equal to 5 on any Sheehan Disability Scale subscale.
  • Willingness to refrain from starting other psychosocial or pharmacological treatments until study completion.

Exclusion criteria

Exclusion Criteria:

  • Patient report of serious medical conditions - such as history of serious, uncontrolled medical illness, or instability (including significant cardio-pulmonary disease, organic brain syndrome, seizure disorder, cerebrovascular disease, thyroid dysfunction, and diabetes)
  • Active suicidal ideation
  • Lifetime history of bipolar disorder, psychosis, mental retardation, or organic brain damage
  • Substance abuse in the last 6 months or dependence within last 12 months.
  • 11 or more cigarettes per week or nicotine equivalent.
  • History of marijuana, cocaine or stimulant use 5-7 times/week or more before age 15 (e.g., amphetamine, cocaine, methamphetamine)
  • Pregnancy
  • Bupropion, dopaminergic or neuroleptic medication use in the past 6 months
  • Heterocyclics and SSRIs are permitted if stabilized (3 months) and PRN benzodiazepines and beta-blockers are permitted but discouraged on laboratory assessment visits
  • Refusal of video/audio-taping
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    Positive Affect Treatment

    15 sessions of psychotherapy designed to augment reward anticipation, reward attainment, and reward learning.

    Behavioral: Positive Affect Treatment

  • Active comparator
    Negative Affect Treatment

    15 sessions of psychotherapy designed to decrease threat avoidance, threat appraisal and arousal.

    Behavioral: Negative Affect Treatment

Interventions

  • BehavioralPositive Affect Treatment

    Sessions 1-7: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects (continued for sessions 8-15) Sessions 8-10: Cognitive exercises focusing on identifying positive aspects of experience, taking responsibility for positive outcomes, and imagining future positive events Sessions 11-14: Exercises to cultivate and savor positive experiences Session 15: Relapse prevention.

  • BehavioralNegative Affect Treatment

    Sessions 1-7: Exposure therapy to feared or avoided situations, sensations, or memories (continued for sessions 8-15) Sessions 8-10: Cognitive restructuring of probability, cost, and attributional biases Sessions 11-14: Capnometry-assisted respiratory training Session 15: Relapse prevention

06

What researchers measure

Primary outcomes

  1. Positive Affect Subscale of the Positive and Negative Affect Scale (PANAS-P)

    Reported positive affect. Scores can range from 10-50, with higher scores representing higher levels of positive affect.

    Time frame: Week 0, Week 5, Week 10, Week 16

  2. Interviewer Anhedonia Ratings

    Interviewer ratings of interest, pleasure, and motivation in hobbies/pastimes, foods/drinks, social activities (score range: 1-12), higher scores indicate lower anhedonia.

    Time frame: Week 0, Week 5, Week 10, Week 16

  3. Depression Anxiety and Stress Scale (DASS-21)

    Reported symptoms of depression, anxiety, and stress (score range: 0-63), higher scores indicate higher symptom severity and frequency.

    Time frame: Week 0, Week 5, Week 10, Week 16

Secondary outcomes

  1. Sheehan Disability Scale (SDS)

    Reported impairment due to symptoms (score range: 0-30) with higher scores indicating greater impairment. Includes reported number of days of missed school/work and number of days of reduced productivity. Statistical analyses have not yet been conducted for this outcome measure.

    Time frame: Week 0, Week 5, Week 10, Week 16

  2. Beck Depression Inventory (BDI)

    Reported suicidal ideation (item 9 on the BDI), scores range from 0-3 with higher scores indicating a higher degree of suicidal ideation. Statistical analyses have not yet been conducted for this outcome measure.

    Time frame: Week 0, Week 5, Week 10, Week 16

  3. Daily Activity/Social Interaction (Actigraph)

    We intended to collect data on energy expenditure over four 7-day periods (at week 0, week 5, week 10, and week 16) using a wrist-worn Actigraph tri-axial accelerometer. However, the use of Actigraph monitors was terminated early in the study due to the onset of the COVID-19 pandemic.

    Time frame: Week 0, Week 5, Week 10, Week 16

  4. Effort Expenditure for Rewards Task (EEfRT)

    The Effort Expenditure for Rewards Task (EEfRT) is a computer-based multi-trial task used to objectively assess decision-making and willingness to expend effort for reward. The dependent variable is the ratio of hard (high-effort) choices to the total number of trials. Results range from 0 to 1, with higher values indicating a higher proportion of hard (high-effort) choices. Results show the mean proportion of high-effort choices.

    Time frame: Week 0, Week 5, Week 10, Week 16

  5. Monetary Incentive Task

    Heart rate acceleration during the Monetary Incentive Task (MIT) was used to measure cardiac responding to the prospect of a monetary reward. The dependent variable is the interbeat interval acceleration during the task (score range in our sample: -0.16 to 0.17). Higher values indicate greater cardiac responding to the prospect of monetary reward.

    Time frame: Week 0, Week 5, Week 10, Week 16

  6. Behavioral Inhibition/Behavioral Activation (Reward Drive Subscale) (BAS-RD)

    Mediator: Reported reward sensitivity (score range: 4-16), with higher scores indicating higher sensitivity

    Time frame: Week 0, Week 5, Week 10, Week 16

  7. Dimensional Anhedonia Rating Scale-Anticipation and Motivation Items

    Mediator: Reported reward desire, motivation, and effort (score range: 0-76) with higher scores indicating higher degree of reward desire, motivation, and effort.

    Time frame: Week 0, Week 5, Week 10, Week 16

  8. Dimensional Anhedonia Rating Scale-Consummatory Items

    Mediator: Reported reward-related pleasure (score range: 0-28), with higher scores indicating higher degree of pleasure.

    Time frame: Week 0, Week 5, Week 10, Week 16

  9. Modified Attentional Dot Probe Task-Disengagement Bias for Negative Stimuli

    The Modified Attentional Dot Probe Task is a computer-based multi-trial task used to objectively assess attentional bias toward positively- and negatively-valenced stimuli. The dependent variable is the reaction time index for disengagement bias from sad faces. This is calculated as follows: (Cue appears proximal to emotional face in the pair of emotional face and random blur image: reaction time for target distal to emotional face minus reaction time for target proximal to emotional face) minus (Cue proximal to neutral face in pair of neutral face and random blur image: reaction time for target distal to neutral face minus reaction time for target proximal to neutral face). The range of values in our sample was: -309.28 to 283.45.

    Time frame: Week 0, Week 5, Week 10, Week 16

  10. Modified Attentional Dot Probe Task-Engagement Bias for Positive Stimuli

    The Modified Attentional Dot Probe Task is a computer-based multi-trial task used to objectively assess attentional bias toward positively- and negatively-valenced stimuli. The dependent variable is the reaction time index for engagement bias from happy faces. This is calculated as follows: (Cue probe distal to negative image in negative/abstract image pair: RT for target probe distal to negative image minus RT for target probe proximal to negative image) minus (Cue probe distal to neutral image in neutral/abstract image pair: RT for target probe distal to neutral image minus RT for target probe proximal to neutral image). The range of data in our sample was: -237.82 to to 343.93. Statistical analyses have not yet been conducted for this outcome measure.

    Time frame: Week 0, Week 5, Week 10, Week 16

  11. International Affective Picture System Task

    Heart rate acceleration during presentation of images from the International Affective Picture Systems (IAPS) was used to assess cardiac responding to positive images. The dependent variable is heart rate acceleration during the 6 seconds of positive image presentation relative to the last 2 seconds before picture onset. Higher values indicate greater cardiac responding to positive images. The range of values in our sample was: -0.12 to 0.09.

    Time frame: Week 0, Week 5, Week 10, Week 16

  12. Temporal Experience of Pleasure Scale (Consummatory Subscale)

    Mediator: Reported reward consummatory pleasure (score range: 8-48), with higher scores indicating higher reported reward consummatory pleasure

    Time frame: Week 0, Week 5, Week 10, Week 16

  13. Probabilistic Reward Task (PRT)

    The Probabilistic Reward Task (PRT) is a computer-based multi-trial task used to objectively assess the propensity to modulate behavior as a function of prior reinforcements. The dependent variable is response bias (measured as accuracy) toward the more frequently rewarded stimulus. A high response bias emerges when subjects show high rates of correct identification (hits) for the rich stimulus and high miss rates for the lean stimulus (i.e., the stimulus associated with less frequent rewards). Higher values indicate a greater propensity to modulate behavior as a function of prior reinforcements. The range of values in our sample was: -0.58 to 0.78.

    Time frame: Week 0, Week 5, Week 10, Week 16

  14. Pavlovian Instrumental Transfer Task - Force (PIT-FORCE)

    The Pavlovian Instrumental Transfer (PIT) task assesses the extent to which a conditional stimulus paired with reward influences instrumental responding to gain rewards. The dependent variable was handgrip force exerted in response to stimuli during a test phase following Pavlovian conditioning. Higher values indicate greater instrumental responding to gain rewards as a function of Pavlovian conditioning to a conditional stimulus paired with reward. The range of values in our sample was: -18.76 to 61.30.

    Time frame: Week 0, Week 5, Week 10, Week 16

  15. Pavlovian Instrumental Transfer Task - Valence (PIT-VALENCE)

    Within the Pavlovian Instrumental Transfer Task (PIT), participants rate the pleasantness (0-4) for three conditional stimuli to indicate the perceived value of reward associated with each one. The dependent variable is the self-reported pleasantness for rewarded stimuli compared to nonrewarded stimuli. This is calculated by first taking the average of participants' pleasantness ratings for the three CS+s and CS-s, and then subtracting the average CS- ratings from the average CS+ ratings. Higher values indicate greater responding to Pavlovian conditioning during the task.

    Time frame: Week 0, Week 5, Week 10, Week 16

07

Results

Posted Dec 7, 2023
Limitations and caveats
Generalizability from academic to community settings; Sample was selected to have low positive affect, thus results may not generalize to samples diagnosed with anhedonia; Lack of follow-up assessment prevented evaluation of long-term changes in target measures and outcomes; Sample powered for moderate or larger effects, while smaller effects may require larger samples; Participants not blinded to condition; NAT was not representative of typical cognitive-behavioral therapy for depression.

Participant flow

Recruitment began February 23, 2019 and ended February 5, 2021. A brief study description was distributed via lab websites, social media, ClinicalTrials.gov, and campus and local area flyers.

Participant flow — Overall Study
MilestonePositive Affect TreatmentNegative Affect Treatment
Started4243
Week 5 assessment3637
Week 10 assessment3229
Completed3126
Not completed1117
Withdrew: Withdrawal by subject1117

Outcome measures

PrimaryPositive Affect Subscale of the Positive and Negative Affect Scale (PANAS-P)

Reported positive affect. Scores can range from 10-50, with higher scores representing higher levels of positive affect.

Time frame:
Week 0, Week 5, Week 10, Week 16
Reported as:
Mean · score on a scale
Positive Affect Subscale of the Positive and Negative Affect Scale (PANAS-P)
score on a scalePositive Affect TreatmentNegative Affect Treatment
Week 020.76 ± 7.4229.42 ± 4.74
Week 524.18 ± 7.3719.42 ± 8.12
Week 1026.88 ± 8.2922.57 ± 9.82
Week 1627.30 ± 7.2323.85 ± 9.28
Statistical analysis
  • Positive Affect Treatment vs Negative Affect Treatment · Mixed Models Analysis · p = .002 (The threshold for statistical significance was p = 0.05. Univariate tests were corrected for false discovery rate using the Benjamin-Hochberg approach.)Baseline levels of outcomes were covaried in all analyses to reduce error variance and correct for group differences.
PrimaryInterviewer Anhedonia Ratings

Interviewer ratings of interest, pleasure, and motivation in hobbies/pastimes, foods/drinks, social activities (score range: 1-12), higher scores indicate lower anhedonia.

Time frame:
Week 0, Week 5, Week 10, Week 16
Reported as:
Mean · score on a scale
Interviewer Anhedonia Ratings
score on a scalePositive Affect TreatmentNegative Affect Treatment
Week 07.66 ± 2.137.47 ± 1.80
Week 56.11 ± 2.265.49 ± 2.40
Week 104.91 ± 2.194.93 ± 2.40
Week 164.19 ± 1.474.43 ± 2.23
Statistical analysis
  • Positive Affect Treatment vs Negative Affect Treatment · Mixed Models Analysis · p = >.05 (The threshold for statistical significance was p = 0.05. Univariate tests were corrected for false discovery rate using the Benjamin-Hochberg approach.)Baseline levels of outcomes were covaried in all analyses to reduce error variance and correct for group differences.
PrimaryDepression Anxiety and Stress Scale (DASS-21)

Reported symptoms of depression, anxiety, and stress (score range: 0-63), higher scores indicate higher symptom severity and frequency.

Time frame:
Week 0, Week 5, Week 10, Week 16
Reported as:
Mean · score on a scale
Depression Anxiety and Stress Scale (DASS-21)
score on a scalePositive Affect TreatmentNegative Affect Treatment
Week 027.36 ± 11.2724.51 ± 10.54
Week 517.90 ± 11.5617.92 ± 10.51
Week 1011.55 ± 9.6013.00 ± 12.13
Week 169.09 ± 6.8512.38 ± 10.90
Statistical analysis
  • Positive Affect Treatment vs Negative Affect Treatment · Mixed Models Analysis · p = .024 (The threshold for statistical significance was p = 0.05. Univariate tests were corrected for false discovery rate using the Benjamin-Hochberg approach.)Baseline levels of outcomes were covaried in all analyses to reduce error variance and correct for group differences.
SecondarySheehan Disability Scale (SDS)

Reported impairment due to symptoms (score range: 0-30) with higher scores indicating greater impairment. Includes reported number of days of missed school/work and number of days of reduced productivity. Statistical analyses have not yet been conducted for this outcome measure.

Time frame:
Week 0, Week 5, Week 10, Week 16
Reported as:
Mean · score on a scale
Sheehan Disability Scale (SDS)
score on a scalePositive Affect TreatmentNegative Affect Treatment
Week 018.40 ± 6.1416.65 ± 6.51
Week 514.53 ± 6.4614.84 ± 6.97
Week 1011.19 ± 6.3411.86 ± 6.94
Week 169.56 ± 6.649.08 ± 6.38
SecondaryBeck Depression Inventory (BDI)

Reported suicidal ideation (item 9 on the BDI), scores range from 0-3 with higher scores indicating a higher degree of suicidal ideation. Statistical analyses have not yet been conducted for this outcome measure.

Time frame:
Week 0, Week 5, Week 10, Week 16
Reported as:
Mean · score on a scale
Beck Depression Inventory (BDI)
score on a scalePositive Affect TreatmentNegative Affect Treatment
Week 00.17 ± 0.380.23 ± 0.43
Week 50.18 ± 0.390.14 ± 0.35
Week 100.18 ± 0.390.20 ± 0.41
Week 160.23 ± 0.430.08 ± 0.27
SecondaryDaily Activity/Social Interaction (Actigraph)

We intended to collect data on energy expenditure over four 7-day periods (at week 0, week 5, week 10, and week 16) using a wrist-worn Actigraph tri-axial accelerometer. However, the use of Actigraph monitors was terminated early in the study due to the onset of the COVID-19 pandemic.

Time frame:
Week 0, Week 5, Week 10, Week 16
Reported as:
Mean · kcals expended per hour
Daily Activity/Social Interaction (Actigraph)
kcals expended per hourPositive Affect TreatmentNegative Affect Treatment
Week 040.212 ± 19.67734.634 ± 24.427
Week 541.98 ± 20.5841.44 ± 26.06
Week 1034.21 ± 20.7546.92 ± 29.33
Week 1643.69 ± 27.1356.57 ± 53.04
SecondaryEffort Expenditure for Rewards Task (EEfRT)

The Effort Expenditure for Rewards Task (EEfRT) is a computer-based multi-trial task used to objectively assess decision-making and willingness to expend effort for reward. The dependent variable is the ratio of hard (high-effort) choices to the total number of trials. Results range from 0 to 1, with higher values indicating a higher proportion of hard (high-effort) choices. Results show the mean proportion of high-effort choices.

Time frame:
Week 0, Week 5, Week 10, Week 16
Reported as:
Mean · proportion of high effort choices
Effort Expenditure for Rewards Task (EEfRT)
proportion of high effort choicesPositive Affect TreatmentNegative Affect Treatment
Week 00.41 ± 0.200.41 ± 0.27
Week 50.43 ± 0.220.39 ± 0.23
Week 100.51 ± 0.260.41 ± 0.31
Week 160.48 ± 0.290.42 ± 0.32
Statistical analysis
  • Positive Affect Treatment vs Negative Affect Treatment · Mixed Models Analysis · p = .922 (The threshold for statistical significance was p = 0.05. Univariate tests were corrected for false discovery rate using the Benjamin-Hochberg approach.)Baseline levels of outcomes were covaried in all analyses to reduce error variance and correct for group differences.
SecondaryMonetary Incentive Task

Heart rate acceleration during the Monetary Incentive Task (MIT) was used to measure cardiac responding to the prospect of a monetary reward. The dependent variable is the interbeat interval acceleration during the task (score range in our sample: -0.16 to 0.17). Higher values indicate greater cardiac responding to the prospect of monetary reward.

Time frame:
Week 0, Week 5, Week 10, Week 16
Reported as:
Mean · beats/ms^2
Monetary Incentive Task
beats/ms^2Positive Affect TreatmentNegative Affect Treatment
Week 0-0.012 ± 0.512-0.017 ± 0.046
Week 50.017 ± 0.0480.013 ± 0.061
Week 10-0.002 ± 0.0420.004 ± 0.043
Week 160.003 ± 0.0260.026 ± 0.053
Statistical analysis
  • Positive Affect Treatment vs Negative Affect Treatment · Mixed Models Analysis · p = .049 (The threshold for statistical significance was p = 0.05. Univariate tests were corrected for false discovery rate using the Benjamin-Hochberg approach.)Baseline levels of outcomes were covaried in all analyses to reduce error variance and correct for group differences.
SecondaryBehavioral Inhibition/Behavioral Activation (Reward Drive Subscale) (BAS-RD)

Mediator: Reported reward sensitivity (score range: 4-16), with higher scores indicating higher sensitivity

Time frame:
Week 0, Week 5, Week 10, Week 16
Reported as:
Mean · score on a scale
Behavioral Inhibition/Behavioral Activation (Reward Drive Subscale) (BAS-RD)
score on a scalePositive Affect TreatmentNegative Affect Treatment
Week 09.67 ± 2.639.42 ± 2.21
Week 510.50 ± 2.6310.14 ± 2.26
Week 1010.66 ± 2.5110.66 ± 2.36
Week 1610.30 ± 2.5611.08 ± 1.96
Statistical analysis
  • Positive Affect Treatment vs Negative Affect Treatment · Mixed Models Analysis · p = .591 (The threshold for statistical significance was p = 0.05. Univariate tests were corrected for false discovery rate using the Benjamin-Hochberg approach.)Baseline levels of outcomes were covaried in all analyses to reduce error variance and correct for group differences.
SecondaryDimensional Anhedonia Rating Scale-Anticipation and Motivation Items

Mediator: Reported reward desire, motivation, and effort (score range: 0-76) with higher scores indicating higher degree of reward desire, motivation, and effort.

Time frame:
Week 0, Week 5, Week 10, Week 16
Reported as:
Mean · score on a scale
Dimensional Anhedonia Rating Scale-Anticipation and Motivation Items
score on a scalePositive Affect TreatmentNegative Affect Treatment
Week 042.85 ± 16.9649.16 ± 16.32
Week 552.28 ± 14.2052.46 ± 15.36
Week 1055.63 ± 15.6955.66 ± 16.08
Week 1659.84 ± 14.3158.46 ± 16.31
Statistical analysis
  • Positive Affect Treatment vs Negative Affect Treatment · Mixed Models Analysis · p = .004 (The threshold for statistical significance was p = 0.05. Univariate tests were corrected for false discovery rate using the Benjamin-Hochberg approach.)Baseline levels of outcomes were covaried in all analyses to reduce error variance and correct for group differences.
SecondaryDimensional Anhedonia Rating Scale-Consummatory Items

Mediator: Reported reward-related pleasure (score range: 0-28), with higher scores indicating higher degree of pleasure.

Time frame:
Week 0, Week 5, Week 10, Week 16
Reported as:
Mean · score on a scale
Dimensional Anhedonia Rating Scale-Consummatory Items
score on a scalePositive Affect TreatmentNegative Affect Treatment
Week 017.56 ± 6.2619.12 ± 6.16
Week 520.39 ± 4.7620.51 ± 6.25
Week 1021.50 ± 5.6621.59 ± 5.99
Week 1622.88 ± 4.7322.12 ± 5.78
Statistical analysis
  • Positive Affect Treatment vs Negative Affect Treatment · Mixed Models Analysis · p = .030 (The threshold for statistical significance was p = 0.05. Univariate tests were corrected for false discovery rate using the Benjamin-Hochberg approach.)Baseline levels of outcomes were covaried in all analyses to reduce error variance and correct for group differences.
SecondaryModified Attentional Dot Probe Task-Disengagement Bias for Negative Stimuli

The Modified Attentional Dot Probe Task is a computer-based multi-trial task used to objectively assess attentional bias toward positively- and negatively-valenced stimuli. The dependent variable is the reaction time index for disengagement bias from sad faces. This is calculated as follows: (Cue appears proximal to emotional face in the pair of emotional face and random blur image: reaction time for target distal to emotional face minus reaction time for target proximal to emotional face) minus (Cue proximal to neutral face in pair of neutral face and random blur image: reaction time for target distal to neutral face minus reaction time for target proximal to neutral face). The range of values in our sample was: -309.28 to 283.45.

Time frame:
Week 0, Week 5, Week 10, Week 16
Reported as:
Mean · milliseconds (ms)
Modified Attentional Dot Probe Task-Disengagement Bias for Negative Stimuli
milliseconds (ms)Positive Affect TreatmentNegative Affect Treatment
Week 0-43.43 ± 114.622.80 ± 105.63
Week 516.70 ± 98.11-16.49 ± 102.44
Week 10-3.07 ± 82.01-31.56 ± 94.05
Week 164.85 ± 97.0066.24 ± 101.47
Statistical analysis
  • Positive Affect Treatment vs Negative Affect Treatment · Mixed Models Analysis · p = .029 (The threshold for statistical significance was p = 0.05. Univariate tests were corrected for false discovery rate using the Benjamin-Hochberg approach.)
SecondaryModified Attentional Dot Probe Task-Engagement Bias for Positive Stimuli

The Modified Attentional Dot Probe Task is a computer-based multi-trial task used to objectively assess attentional bias toward positively- and negatively-valenced stimuli. The dependent variable is the reaction time index for engagement bias from happy faces. This is calculated as follows: (Cue probe distal to negative image in negative/abstract image pair: RT for target probe distal to negative image minus RT for target probe proximal to negative image) minus (Cue probe distal to neutral image in neutral/abstract image pair: RT for target probe distal to neutral image minus RT for target probe proximal to neutral image). The range of data in our sample was: -237.82 to to 343.93. Statistical analyses have not yet been conducted for this outcome measure.

Time frame:
Week 0, Week 5, Week 10, Week 16
Reported as:
Mean · milliseconds (ms)
Modified Attentional Dot Probe Task-Engagement Bias for Positive Stimuli
milliseconds (ms)Positive Affect TreatmentNegative Affect Treatment
Week 09.30 ± 105.873.29 ± 108.57
Week 5-17.65 ± 90.722.62 ± 96.57
Week 10-20.86 ± 69.89-22.51 ± 88.93
Week 16-22.51 ± 89.9316.36 ± 111.56
SecondaryInternational Affective Picture System Task

Heart rate acceleration during presentation of images from the International Affective Picture Systems (IAPS) was used to assess cardiac responding to positive images. The dependent variable is heart rate acceleration during the 6 seconds of positive image presentation relative to the last 2 seconds before picture onset. Higher values indicate greater cardiac responding to positive images. The range of values in our sample was: -0.12 to 0.09.

Time frame:
Week 0, Week 5, Week 10, Week 16
Reported as:
Mean · beats/ms^2
International Affective Picture System Task
beats/ms^2Positive Affect TreatmentNegative Affect Treatment
Week 00.0003 ± 0.0243-0.0007 ± 0.0238
Week 5-0.0016 ± 0.0222-0.0061 ± 0.0331
Week 100.0071 ± 0.02210.0013 ± 0.0244
Week 160.0024 ± 0.02220.0035 ± 0.0524
Statistical analysis
  • Positive Affect Treatment vs Negative Affect Treatment · Mixed Models Analysis · p = .494 (The threshold for statistical significance was p = 0.05. Univariate tests were corrected for false discovery rate using the Benjamin-Hochberg approach.)Baseline levels of outcomes were covaried in all analyses to reduce error variance and correct for group differences.
SecondaryTemporal Experience of Pleasure Scale (Consummatory Subscale)

Mediator: Reported reward consummatory pleasure (score range: 8-48), with higher scores indicating higher reported reward consummatory pleasure

Time frame:
Week 0, Week 5, Week 10, Week 16
Reported as:
Mean · score on a scale
Temporal Experience of Pleasure Scale (Consummatory Subscale)
score on a scalePositive Affect TreatmentNegative Affect Treatment
Week 035.81 ± 6.9837.12 ± 6.03
Week 536.28 ± 6.2037.49 ± 5.83
Week 1037.03 ± 6.1737.97 ± 5.17
Week 1637.70 ± 4.7337.62 ± 5.59
Statistical analysis
  • Positive Affect Treatment vs Negative Affect Treatment · Mixed Models Analysis · p = .231 (The threshold for statistical significance was p = 0.05. Univariate tests were corrected for false discovery rate using the Benjamin-Hochberg approach.)Baseline levels of outcomes were covaried in all analyses to reduce error variance and correct for group differences.
SecondaryProbabilistic Reward Task (PRT)

The Probabilistic Reward Task (PRT) is a computer-based multi-trial task used to objectively assess the propensity to modulate behavior as a function of prior reinforcements. The dependent variable is response bias (measured as accuracy) toward the more frequently rewarded stimulus. A high response bias emerges when subjects show high rates of correct identification (hits) for the rich stimulus and high miss rates for the lean stimulus (i.e., the stimulus associated with less frequent rewards). Higher values indicate a greater propensity to modulate behavior as a function of prior reinforcements. The range of values in our sample was: -0.58 to 0.78.

Time frame:
Week 0, Week 5, Week 10, Week 16
Reported as:
Mean · Ratio
Probabilistic Reward Task (PRT)
RatioPositive Affect TreatmentNegative Affect Treatment
Week 00.16 ± 0.190.15 ± 0.29
Week 50.04 ± 0.270.19 ± 0.27
Week 100.09 ± 0.130.03 ± 0.18
Week 160.16 ± 0.210.15 ± 0.23
Statistical analysis
  • Positive Affect Treatment vs Negative Affect Treatment · Mixed Models Analysis · p = .344 (The threshold for statistical significance was p = 0.05. Univariate tests were corrected for false discovery rate using the Benjamin-Hochberg approach.)Baseline levels of outcomes were covaried in all analyses to reduce error variance and correct for group differences.
SecondaryPavlovian Instrumental Transfer Task - Force (PIT-FORCE)

The Pavlovian Instrumental Transfer (PIT) task assesses the extent to which a conditional stimulus paired with reward influences instrumental responding to gain rewards. The dependent variable was handgrip force exerted in response to stimuli during a test phase following Pavlovian conditioning. Higher values indicate greater instrumental responding to gain rewards as a function of Pavlovian conditioning to a conditional stimulus paired with reward. The range of values in our sample was: -18.76 to 61.30.

Time frame:
Week 0, Week 5, Week 10, Week 16
Reported as:
Mean · volts
Pavlovian Instrumental Transfer Task - Force (PIT-FORCE)
voltsPositive Affect TreatmentNegative Affect Treatment
Week 06.30 ± 12.294.91 ± 13.54
Week 57.96 ± 15.616.72 ± 12.60
Week 106.55 ± 16.396.57 ± 12.35
Week 168.05 ± 16.341.24 ± 7.96
Statistical analysis
  • Positive Affect Treatment vs Negative Affect Treatment · Mixed Models Analysis · p = .267 (The threshold for statistical significance was p = 0.05. Univariate tests were corrected for false discovery rate using the Benjamin-Hochberg approach.)Baseline levels of outcomes were covaried in all analyses to reduce error variance and correct for group differences.
SecondaryPavlovian Instrumental Transfer Task - Valence (PIT-VALENCE)

Within the Pavlovian Instrumental Transfer Task (PIT), participants rate the pleasantness (0-4) for three conditional stimuli to indicate the perceived value of reward associated with each one. The dependent variable is the self-reported pleasantness for rewarded stimuli compared to nonrewarded stimuli. This is calculated by first taking the average of participants' pleasantness ratings for the three CS+s and CS-s, and then subtracting the average CS- ratings from the average CS+ ratings. Higher values indicate greater responding to Pavlovian conditioning during the task.

Time frame:
Week 0, Week 5, Week 10, Week 16
Reported as:
Mean · score on a scale
Pavlovian Instrumental Transfer Task - Valence (PIT-VALENCE)
score on a scalePositive Affect TreatmentNegative Affect Treatment
Week 01.09 ± 2.100.62 ± 2.17
Week 51.50 ± 2.500.73 ± 2.99
Week 101.29 ± 2.880.44 ± 2.94
Week 160.74 ± 2.491.93 ± 1.90
Statistical analysis
  • Positive Affect Treatment vs Negative Affect Treatment · Mixed Models Analysis · p = .051 (The threshold for statistical significance was p = 0.05. Univariate tests were corrected for false discovery rate using the Benjamin-Hochberg approach.)Baseline levels of outcomes were covaried in all analyses to reduce error variance and correct for group differences.

Adverse events

Collected over Each participant was assessed over 16 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Positive Affect Treatment0/42 (0%)0/42 (0%)0/42 (0%)
Negative Affect Treatment0/43 (0%)0/43 (0%)3/43 (7%)
Most frequent other events
Most frequent other events
EventPositive Affect TreatmentNegative Affect Treatment
Clinical deteriorationPsychiatric disorders0/422/43
Homework noncompliance leading to participant withdrawalPsychiatric disorders0/421/43

Baseline characteristics

Age, Continuous
Age, Continuous(years)Positive Affect TreatmentNegative Affect TreatmentTotal
Mean31.95 ± 11.531.51 ± 13.131.73 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)Positive Affect TreatmentNegative Affect TreatmentTotal
Female313667
Male11718
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Positive Affect TreatmentNegative Affect TreatmentTotal
White282553
Asian8917
Alaska Native/Native American/Indigenous101
Pacific Islander/Native Hawaiian011
Black or African American235
Hispanic/Latino (White)6915
Hispanic/Latino (non-White)448
Multiracial314
Other178
Marital status
Marital status(Participants)Positive Affect TreatmentNegative Affect TreatmentTotal
Married91019
Single, in a relationship101323
Single, not in a relationship191938
Separated112
Divorced303
Current psychotropic medication
Current psychotropic medication(Participants)Positive Affect TreatmentNegative Affect TreatmentTotal
Count of participants121224
Any diagnosis
Any diagnosis(Participants)Positive Affect TreatmentNegative Affect TreatmentTotal
Count of participants373976
Depressive diagnoses
Depressive diagnoses(Participants)Positive Affect TreatmentNegative Affect TreatmentTotal
Count of participants273158
Major depressive disorder
Major depressive disorder(Participants)Positive Affect TreatmentNegative Affect TreatmentTotal
Count of participants192746

11 further baseline measures are reported on the registry.

08

Study locations

2 sites
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
  • Southern Methodist University
    Dallas, Texas 75205, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Jun 2021, 28 months.

Results were first posted in Dec 2023, 2 years 5 months after primary completion.

Of 3,471 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 28 months is above that.

Counting every sponsor, half of 3,569 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2018
First posted
Feb 20, 2018
StartActual
Feb 1, 2019
Primary completionActual
Jun 30, 2021
CompletionActual
Jun 30, 2021
Results first posted
Dec 7, 2023
Last update
Jun 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03439748
Collaborators
Southern Methodist University
Responsible party
Michelle Craske (Principal Investigator, University of California, Los Angeles) — Principal investigator
First posted
Feb 20, 2018
Start date
Feb 1, 2019
Primary completion
Jun 30, 2021
Completion
Jun 30, 2021
Results posted
Dec 7, 2023
Last update
Jun 12, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion